5,7-二氟色胺盐酸盐 | 159730-14-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5,7-二氟色胺盐酸盐
• 中文别名: 2-(5,7-二氟-1H-吲哚-3-基)乙胺盐酸盐
• 英文名称: 2-(5,7-difluoro-1H-indol-3-yl)ethan-1-amine hydrochloride
• 英文别名: 5,7-difluorotryptamine hydrochloride；2-(5,7-difluoro-1H-indol-3-yl)ethanamine;hydrochloride
• CAS: 159730-14-0
• 化学式: C₁₀H₁₀F₂N₂*ClH
• 分子量: 232.661
• InChiKey: LYCXIRODMNCMJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.37
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  41.8
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  (Z)-4-(3,4-dimethoxybenzylidene)-2-methyl-5(4H)-oxazolone 、 5,7-二氟色胺盐酸盐 在 盐酸 作用下， 生成 6,8-difluoro-1-[(3,4-dimethoxyphenyl)-methyl]-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole
  参考文献：
  名称：

  Potent, Selective Tetrahydro-β-carboline Antagonists of the Serotonin 2B (5HT_2B) Contractile Receptor in the Rat Stomach Fundus

  摘要：

  A series of potent, selective 5HT(2B) receptor antagonists has been identified based upon yohimbine, with SAR studies resulting in a 1000-fold increase in 5HT(2B) receptor affinity relative to the starting structure (-log K(B)s > 10.0 have been obtained). These high-affinity tetrahydro-beta-carboline antagonists are able to discriminate among the 5HT(2) family of serotonin receptors, with members of the series showing selectivities of more than 100-fold versus both the 5HT(2A) and 5HT(2C) receptors based upon radioligand binding and functional assays. As the first compounds reported with such selectivity and enhanced receptor affinity, these tetrahydro-beta-carboline antagonists are useful tools for elucidating the role of serotonin acting at the 5HT(2B) receptor in normal and disease physiology.

  DOI：

  10.1021/jm960062t

文献信息

• [EN] FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERARY<br/>[FR] DIAMIDES IMIDODICARBONIMIDIQUES LIÉS À UN ALKYLÈNE BICYCLIQUE FUSIONNÉ, PROCÉDÉS DE SYNTHÈSE ET UTILISATIONS DANS UNE THÉRAPIE
  申请人：NOVATARG INC

  公开号：WO2018106907A1

  公开（公告）日：2018-06-14

  The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3- yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3- yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5' adenosine monophosphate-activated protein kinase (AMPK).

  本发明提供了新型的融合的双环烷基亚乙基连接的咪唑二氨基碳亚胺二酰胺。具体来说，本文描述了N-[2-(吲哚-3-基)烷基]-连接的咪唑二氨基碳亚胺二酰胺和N-[2-(吡咯吡啶-3-基)烷基]-连接的咪唑二氨基碳亚胺二酰胺（化合物的结构式（I）或结构式（II）），以及其用途。本发明的化合物被认为是有机阳离子转运体选择性化合物，可用于治疗由于5'腺苷单磷酸活化蛋白激酶（AMPK）活性降低而引起的疾病和症状。
• [EN] METHOD FOR TREATING 5HT2B RECEPTOR RELATED CONDITIONS<br/>[FR] METHODE DE TRAITEMENT D'ETATS ASSOCIES AU RECEPTEUR 5HT2B
  申请人：ELI LILLY AND COMPANY

  公开号：WO1995024200A1

  公开（公告）日：1995-09-14

  (EN) The present invention provides methods for binding a 5-HT2B receptor in mammals using both known and novel compounds. Further, the invention provides a method for treating or preventing 5-HT2B related conditions. Finally, the invention provides an article of manufacture.(FR) L'invention concerne des méthodes de fixation du récepteur 5-HT2B chez les mammifères au moyen de composés connus et nouveaux, ainsi qu'une méthode de traitement ou de prévention d'états associés à 5-HT2B. Un article manufacturé est également décrit.

  (EN) 本发明提供了一种使用已知和新颖化合物来结合哺乳动物中的5-HT2B受体的方法。此外，本发明还提供了一种用于治疗或预防5-HT2B相关疾病的方法。最后，本发明提供了一种制品。 (FR) La présente invention concerne des méthodes de fixation du récepteur 5-HT2B chez les mammifères au moyen de composés connus et nouveaux, ainsi qu'une méthode de traitement ou de prévention d'états associés à 5-HT2B. Un article manufacturé est également décrit.
• Tetrahydro-beta-carbolines
  申请人：ELI LILLY AND COMPANY

  公开号：EP0620222A2

  公开（公告）日：1994-10-19

  The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided 3-ethanamine and 3-ethanamine related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds.

  本发明提供了具有有益中枢神经系统活性的新型四氢-beta-咔啉化合物。此外，本发明还提供了 3-乙胺和 3-乙胺相关化合物，它们是有用的中间体，具有有益的中枢神经系统活性。本发明提供了使用新型四氢-beta-咔啉和相关化合物的配方和方法。
• Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
  申请人：NovaTarg, Inc.

  公开号：US11261157B2

  公开（公告）日：2022-03-01

  The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5′ adenosine monophosphate-activated protein kinase (AMPK).

  本发明提供了新颖的融合双环烯基连接的咪唑二碳酰亚胺二酰胺。特别是，本发明描述了 N-[2-(吲哚-3-基)亚烷基]连接的咪唑二碳酰亚胺二酰胺和 N-[2-(吡咯并吡啶-3-基)亚烷基]连接的咪唑二碳酰亚胺二酰胺（式 (I) 或式 (II) 的化合物）及其用途。本发明的化合物被认为是有机阳离子转运体选择性化合物，可用于治疗由 5′单磷酸腺苷激活蛋白激酶（AMPK）活性降低引起的疾病和病症。
• METHOD FOR TREATING 5HT 2B RECEPTOR RELATED CONDITIONS
  申请人：ELI LILLY AND COMPANY

  公开号：EP0749313A1

  公开（公告）日：1996-12-27